Key points are not available for this paper at this time.
To provide a European perspective, I was invited to sit on the Institute of Medicine (IOM) committee that was charged with assessing the current system for evaluating and ensuring postmarketing drug safety in the United States. My colleagues on the committee came from a variety of professional backgrounds (health care, epidemiology, law, and economics), and the committee was managed by an experienced IOM staff member.1 Clinical Pharmacology & Therapeutics (2007) 81, 161–163. doi:10.1038/sj.clpt.6100079
AM Breckenridge (Thu,) studied this question.